Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Menu

Merus N.V. CS (MRUS)

Merus N.V. CS (MRUS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Merus N.V. Announces First Patient Dosed in Phase 2 Trial of Petosemtamab for Metastatic Colorectal Cancer Quiver Quantitative, Inc. - Tue Dec 17, 1:24AM CST

Merus N.V. has dosed the first patient in a phase 2 trial of petosemtamab for metastatic colorectal cancer.Quiver AI SummaryMerus N.V. has announced the dosing of the first patient in a phase 2 trial assessing...

MRUS : 41.85 (-0.57%)
Merus N.V. Updates on Petosemtamab Clinical Trials in Head and Neck Squamous Cell Carcinoma and Metastatic Colorectal Cancer Quiver Quantitative, Inc. - Sat Dec 7, 10:42AM CST

Merus announces ongoing trials of petosemtamab for head and neck and colorectal cancers, with data updates expected in 2025.Quiver AI SummaryMerus N.V. announced interim clinical results from its ongoing...

MRUS : 41.85 (-0.57%)
Merus N.V. Receives FDA Approval for BIZENGRI®: First Targeted Therapy for NRG1+ Advanced Pancreatic Adenocarcinoma and NSCLC Quiver Quantitative, Inc. - Thu Dec 5, 2:08AM CST

BIZENGRI® is the FDA-approved therapy for advanced pancreatic adenocarcinoma and NSCLC with NRG1 gene fusions, offering new treatment options.Quiver AI SummaryMerus N.V. has announced that the U.S. FDA...

MRUS : 41.85 (-0.57%)
Merus N.V. Announces Positive Phase 2 Interim Data for Petosemtamab Monotherapy in Second-Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Quiver Quantitative, Inc. - Sun Dec 1, 8:16PM CST

Petosemtamab shows promising results in treating recurrent/metastatic HNSCC; full data to be discussed on December 7.Quiver AI SummaryMerus N.V. announced the interim data from a Phase 2 trial of petosemtamab...

MRUS : 41.85 (-0.57%)
Biotech Innovations: Revolutionary Treatments Aim to Boost Pancreatic Cancer Survival Rates Newswire.ca - Mon Aug 12, 3:37PM CDT

/CNW/ -- USA News Group – Pancreatic cancer is among the deadliest cancers, prompting researchers to focus on early detection to improve survival rates. Johns...

ONCY : 0.8310 (-6.36%)
HALO : 46.96 (-0.76%)
CADL : 8.75 (-12.15%)
MRUS : 41.85 (-0.57%)
RHHBY : 34.5000 (+0.76%)
ONC.TO : 1.19 (-9.16%)
Biotech Innovations Poised to Transform Pancreatic Cancer Treatment and Patient Outcomes BayStreet.ca - Mon Aug 12, 12:44PM CDT

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – USA News Group – Pancreatic cancer is among the...

ONCY : 0.8310 (-6.36%)
ONC.TO : 1.19 (-9.16%)
RHHBY : 34.5000 (+0.76%)
HALO : 46.96 (-0.76%)
CADL : 8.75 (-12.15%)
MRUS : 41.85 (-0.57%)
Pancreatic Cancer Battle Intensifies: Biotech Innovations Aim to Boost Survival Rates Newswire.ca - Thu May 23, 10:51AM CDT

/CNW/ -- USA News Group – Known as one of the deadliest cancers, researchers are working diligently to help increase the chance of survival for pancreatic...

ONCY : 0.8310 (-6.36%)
CADL : 8.75 (-12.15%)
AZN : 65.35 (+1.41%)
MRUS : 41.85 (-0.57%)
LTRN : 3.14 (-2.02%)
ONC.TO : 1.19 (-9.16%)
Biotech Developers Pioneer New Treatments, Aiming to Reduce Pancreatic Cancer Fatalities in 2024 BayStreet.ca - Thu May 23, 8:32AM CDT

USA News Group – Known as one of the deadliest cancers, researchers are working diligently to help increase the chance of survival for pancreatic cancer patients through earlier detection, as according...

ONCY : 0.8310 (-6.36%)
ONC.TO : 1.19 (-9.16%)
CADL : 8.75 (-12.15%)
AZN : 65.35 (+1.41%)
MRUS : 41.85 (-0.57%)
LTRN : 3.14 (-2.02%)
Pancreatic Cancer Battle Intensifies with Biotech Sector's Advanced Treatments BayStreet.ca - Fri May 17, 10:48AM CDT

USA News Group – A new study is bringing hope in the fight against one of the deadliest cancers, revealing a blood test that can detect early-stage pancreatic cancer with 97% accuracy. This breakthrough...

ONCY : 0.8310 (-6.36%)
ONC.TO : 1.19 (-9.16%)
RHHBY : 34.5000 (+0.76%)
MRUS : 41.85 (-0.57%)
MGNX : 3.18 (unch)
IMRX : 2.00 (+8.70%)
New FDA Designations Accelerate Progress in Pancreatic Cancer Treatments: A Year in Review FinancialNewsMedia - Fri Oct 13, 2023

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:PYXS),(NASDAQ:AZN),(NYSE:LLY),(NASDAQ:MRUS) EQNX::TICKER_END

ONCY : 0.8310 (-6.36%)
ONC.TO : 1.19 (-9.16%)
PYXS : 1.6900 (+9.74%)
AZN : 65.35 (+1.41%)
LLY : 767.76 (+1.35%)
MRUS : 41.85 (-0.57%)

Barchart Exclusives

Scalp a 47% Payout by the End of This Week with Micron (MU) Call Spreads Barchart - Sat Dec 21, 9:15AM CST
Yes, there are serious questions about MU stock following the underlying company’s disappointing earnings but a steady march is all options traders need. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot